Prospective evaluation of changes in choroidal vascularity index after half-dose photodynamic therapy versus micropulse laser treatment in chronic central serous chorioretinopathy

被引:25
|
作者
van Rijssen, Thomas J. [1 ]
Singh, Sumit Randhir [2 ]
van Dijk, Elon H. C. [1 ]
Rasheed, Mohammed A. [2 ]
Vupparaboina, Kiran Kumar [2 ]
Boon, Camiel J. F. [1 ,3 ]
Chhablani, Jay [4 ]
机构
[1] Leiden Univ, Med Ctr, Dept Ophthalmol, Leiden, Netherlands
[2] LV Prasad Eye Inst, Dept Ophthalmol, Hyderabad, India
[3] Univ Amsterdam, Acad Med Ctr, Dept Ophthalmol, Amsterdam, Netherlands
[4] Univ Pittsburgh, Dept Ophthalmol, UPMC Eye Ctr, Pittsburgh, PA 15260 USA
关键词
Central serous chorioretinopathy; Choroidal vascularity index; Micropulse laser; Photodynamic therapy; PHOTOCOAGULATION; PATHOPHYSIOLOGY; EPLERENONE; THICKNESS; UPDATE; AREAS;
D O I
10.1007/s00417-020-04619-6
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose To assess whether treatment of chronic central serous chorioretinopathy (cCSC) with photodynamic therapy (PDT) and high-density subthreshold micropulse laser (HSML) results in choroidal vascularity index (CVI) changes that may account for the treatment effect. Methods Patients with cCSC were prospectively included and analyzed. Patients received either half-dose PDT or HSML treatment. CVI of the affected and unaffected eye was obtained before treatment, 6 to 8 weeks after treatment, and 7 to 8 months after treatment. Results At baseline, 29 eyes (29 patients) were included both in the PDT and in the HSML group. The mean (+/- standard deviation) CVI change in the HSML group between before PDT and 6 to 8 weeks after PDT was - 0.009 +/- 0.032 (p = 0.127), whereas this was 0.0025 +/- 0.037 (p = 0.723) between the visit before PDT and final visit. The patients in the PDT group had a CVI change of - 0.0025 +/- 0.037 (p = 0.723) between the visit before PDT and first visit after PDT, and a mean CVI change of - 0.013 +/- 0.038 (p = 0.080) between the visit before PDT and final visit. There was no significant correlation between CVI and BCVA at the measured time points, in both the HSML group (p = 0.885), and in the PDT group (p = 0.904). Moreover, no significant changes in CVI occurred in the unaffected eye at any time point. Conclusions PDT and HSML do not significantly affect CVI, and therefore a CVI change may not be primarily responsible for the treatment effect. The positive treatment effect of both interventions may rely on other mechanisms, such as an effect on choriocapillaris and/or retinal pigment epithelium function.
引用
收藏
页码:1191 / 1197
页数:7
相关论文
共 50 条
  • [21] Choroidal hemodynamics in central serous chorioretinopathy after half-dose photodynamic therapy and the effects of smoking
    Horiguchi, Etsuyo
    Takeuchi, Jun
    Tomita, Ryo
    Asai, Keiko
    Nakano, Yuyako
    Ota, Hikaru
    Taki, Yosuke
    Ito, Yasuki
    Terasaki, Hiroko
    Nishiguchi, Koji M.
    Kataoka, Keiko
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [22] Comprehensive evaluation of intravitreal conbercept versus half-dose photodynamic therapy for chronic central serous chorioretinopathy
    Mao, Jian-Bo
    Zhang, Cai-Yun
    Liu, Chen-Yi
    Zhang, Yun
    Lin, Jing-Jing
    Xu, Zhao-Kai
    Chen, Yi-Qi
    Fan, Yuan-Yuan
    Zhao, Shi-Xin
    Shen, Li-Jun
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2021, 14 (05) : 719 - 724
  • [23] Comprehensive evaluation of intravitreal conbercept versus half-dose photodynamic therapy for chronic central serous chorioretinopathy
    Jian-Bo Mao
    Cai-Yun Zhang
    Chen-Yi Liu
    Yun Zhang
    Jing-Jing Lin
    Zhao-Kai Xu
    Yi-Qi Chen
    Yuan-Yuan Fan
    Shi-Xin Zhao
    Li-Jun Shen
    International Journal of Ophthalmology, 2021, 14 (05) : 719 - 724
  • [24] Choroidal neovascularization secondary to half-dose photodynamic therapy for chronic central serous chorioretinopathy A case report
    Zhang, Zhengwei
    Bao, Xiaona
    Wu, Zhifeng
    Zhang, Jie
    MEDICINE, 2021, 100 (07) : E24790
  • [25] Infographic: Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial
    Yusuf, Imran H.
    Henein, Christin
    Sivaprasad, Sobha
    EYE, 2024, 38 (SUPPL 2) : 35 - 36
  • [26] Half-fluence Versus Half-dose Photodynamic Therapy in Chronic Central Serous Chorioretinopathy REPLY
    Nicolo, Massimo
    Traverso, Carlo Enrico
    Musetti, Donatella
    Piccolino, Felice Cardillo
    Eandi, Chiara M.
    Alovisi, Camilla
    Grignolo, Federico M.
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2015, 159 (01) : 205 - 206
  • [27] Randomized Clinical Trial to Compare Micropulse Photocoagulation Versus Half-dose Verteporfin Photodynamic Therapy in the Treatment of Central Serous Chorioretinopathy
    Kretz, Florian T. A.
    Beger, Isabell
    Koch, Frank
    Nowomiejska, Katarrzyna
    Auffarth, Gerd U.
    Koss, Michael J.
    OPHTHALMIC SURGERY LASERS & IMAGING RETINA, 2015, 46 (08): : 837 - 843
  • [28] Response to 'Comment on 'Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy"
    Scholz, P.
    Altay, L.
    Fauser, S.
    EYE, 2017, 31 (02) : 346 - 346
  • [29] Half-dose Versus Half-time Photodynamic Therapy for Central Serous Chorioretinopathy
    Liu, Hsin-Yu
    Yang, Chang-Hao
    Yang, Chung-May
    Ho, Tzyy-Chang
    Lin, Chang-Ping
    Hsieh, Yi-Ting
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2016, 167 : 57 - 64
  • [30] Response to ‘Comment on ‘Comparison of subthreshold micropulse laser (577 nm) treatment and half-dose photodynamic therapy in patients with chronic central serous chorioretinopathy’’
    P Scholz
    L Altay
    S Fauser
    Eye, 2017, 31 : 346 - 346